The recent announcement that Pope Leo XIV has been diagnosed with lung adenocarcinoma has brought renewed attention to one of the most common forms of lung cancer—and to the significant progress being made in how the disease is detected and treated.
The Vatican announced that the Pope’s cancer was identified following surgery to remove the lower lobe of his right lung. While details about his cancer stage and any additional treatment have not been publicly confirmed, his diagnosis provides an opportunity to increase awareness and understanding of lung cancer.
Dr. Wade Iams, the Director of Lung Cancer Research at the Greco Hainsworth Centers for Research at Tennessee Oncology, emphasizes that every lung cancer diagnosis is different and treatment decisions depend on several factors, including the type and stage of the cancer and its molecular characteristics.
Dr. Iams shares, “When people hear ‘lung cancer,’ they may think there is one disease with one treatment approach, but lung cancer care has become increasingly personalized. We now have sophisticated tools to understand the biology of an individual patient’s cancer and a growing range of treatments, including targeted therapies and immunotherapy as standard options or newer versions in clinical trials. Early detection remains critically important because finding lung cancer before it has spread can significantly expand the treatment options available to a patient.”
Understanding Lung Adenocarcinoma
Lung adenocarcinoma is the most common subtype of non-small cell lung cancer. Although tobacco use remains an important risk factor for lung cancer, adenocarcinoma can also occur in people who have never smoked.
For people at increased risk, lung cancer screening with a low-dose CT scan can help detect the disease at an earlier stage, sometimes before symptoms appear. Patients should talk with their healthcare provider about whether lung cancer screening is appropriate for them.
A New Era of Personalized Treatment
Treatment for lung cancer has advanced considerably in the past decade. Depending on the cancer’s stage and characteristics, treatment may involve surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or a combination of approaches. An increasingly important part of lung cancer care is biomarker testing, which allows oncologists to identify specific molecular characteristics in a patient’s tumor. These results help identify the best treatment for each individual patient. Dr. Iams has contributed to research focused on improving lung cancer treatment and advancing personalized approaches to care.
Turning Awareness Into Action
While it would be inappropriate to speculate about Pope Leo XIV’s prognosis or future treatment without additional clinical information, his diagnosis offers an important reminder: lung cancer can affect people from many backgrounds, early detection matters, and treatment continues to evolve.
For patients and families facing lung cancer, understanding the specific diagnosis and working with an experienced cancer care team are important first steps toward developing an individualized treatment plan.
Learn more about Dr. Wade Iams and lung cancer care at Tennessee Oncology.
